Loading…
Loading…
Charles River (CRL) reported earnings 30 days ago. What's next for the stock?
Charles River's improving DSA demand and strategic investments support growth, but uneven recovery and NHP cost volatility remain key risks.
Charles River Laboratories International (NYSE: CRL - Get Free Report) and IB Acquisition (NASDAQ: IBAC - Get Free Report) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, profitability, dividends, analyst recommendations, valuation, risk and institutional ownership. Earnings and Valuation This table compares
According to prediction markets, final passage of the Clarity Act is not likely to happen until mid-2027 at the earliest. If the Clarity Act stalls out in Congress, the crypto industry will need to rely on favorable rule making from the likes of the SEC, CFTC, and OCC.
Great Lakes Advisors LLC purchased a new position in shares of Charles River Laboratories International, Inc. (NYSE: CRL) during the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 2,026 shares of the medical research company's stock, valued at approximately $459,000. A
Charles River's 33.3% monthly surge faces a higher bar as stronger bookings and guidance meet margin pressure and a premium valuation.
CRL's shares have surged 88.6% in a year as DSA returns to organic growth, bookings climb and new testing initiatives broaden its strategy.
On June 30, 2026, John Rogers (Trades, Portfolio), through Ariel Investment, LLC, executed a significant reduction in the firm's position in Sphere Entertainmen